Home > Inhibitors & Agonists
Cat. No. Product name CAS No.
DCC3393 Mk-386

Potent and selective human type-1 5alpha-reductase inhibitor

158493-17-5
DCC3394 Mk-4541

Novel Selective Androgen Receptor Modulator (SARM)

796885-38-6
DCC3395 Mk-5046

Novel nonpeptide bombesin receptor subtype-3 agonist

1022152-70-0
DCC3396 Mk-6884

Novel potent muscarinic acetylcholine receptor 4 (M4) positive allosteric modulator (PAM)

DCC3397 Mk-7725

Novel bombesin receptor subtype-3 (BRS-3) modulator

1034152-95-8
DCC3398 Mk-8245 Analog

Novel liver-targeting inhibitor of stearoyl-CoA desaturase (SCD)

1030612-87-3
DCC3399 Mk-8666 Tromethamine

Novel agonist of G-protein coupled receptor 40 (GPR40)

2056254-98-7
DCC3400 Mk-8970

Prodrug of raltegravir with enhanced colonic absorption

DCC3401 Mkk3/6-in-6

Novel potent and selective MKK3/6 inhibitor

DCC3402 Mkp5-in-1

Novel highly specific, potent, orally bioavailable MKP5 inhibitor

DCC3403 Km04794

Novel endoplasmic reticulum proteostasis modulator, enhancing insulin production in pancreatic β cells, inhibiting the UPR, alleviating ER stress and protein aggregation, improving intracellular insulin levels and insulin secretion

882287-24-3
DCC3404 ml312

Novel Inhibitor of Scavenger Receptor BI-mediated Lipid Uptake

1223559-59-8
DCC3405 Mlck Inhibitor Peptide-18

Selective inhibitor of Myosin Light Chain Kinase (MLCK)

224579-74-2
DCC3406 Mln-0415

Novel IKK2 inhibitor, decreasing NF-κB activation and down-regulating the expression of a number of inflammatory proteins

1147862-78-9
DCC3407 Mln944

Novel potent DNA binding agent, stabilizing topoisomerase-dependent cleavage, demonstrating exceptional efficacy against a number of murine and human tumor models

343247-32-5
DCC3408 Mln-977

Second generation 5-LO inhibitor, blocking the production of leukotrienes

175212-04-1
DCC3409 Mls000099089

Novel selective and potent inhibitor of recombinant h12/15-LOX and cellular mouse 12/15-LOX (m12/15-LOX)

1164497-58-8
DCC3410 Mls000536924

Potent and selective competitive inhibitor of human epithelial 15-lipoxygenase-2 (15-LOX-2)

511306-37-9
DCC3411 Mls000545091

Potent and selective mixed-type inhibitor of human epithelial 15-lipoxygenase-2 (15-LOX-2)

322666-76-2
DCC3412 Mls000733230

Novel potent inhibitor of EBOV infection

DCC3413 Mls001158554

Novel Inhibitor of Human Cytomegalovirus

DCC3414 Mls-2064

Potent inhibitor of STAT3 and Akt signaling

906660-74-0
DCC3415 Mls-2384

Novel dual JAK/Src kinase inhibitor, suppressing growth of diverse cancer cells

1067884-45-0
DCC3416 Mls8091

Novel inhibitor of human cytomegalovirus (HCMV) infection

848217-46-9
DCC3417 Ml-sa3

Potent agonist of TRPML channels specifically activating lysosomal ML1 currents

570381-68-9
DCC3418 Mlt-695

Novel potent and selective MALT-1 protease inhibitor, showing improved solubility and permeability in comparison with MLT-748

DCC3419 Mmg-0358

Novel potent IDO1 inhibitor, showing low cytotoxicity and higher selectivity for IDO1 over TDO enzyme

1378976-02-3
DCC3420 Mmh371

Novel potent and selective HDAC8 inhibitor

DCC3421 Mmh409

Novel potent and selective HDAC8 inhibitor

DCC3422 Mmh410

Novel potent and selective HDAC8 inhibitor

DCC3423 Mmp13-in-t26c

Novel highly potent and selective MMP13 inhibitor

869298-22-6
DCC3424 M-mpep

Negative allosteric modulator (NAM) ligand for the mGlu5 receptor

DCC3425 Mmpl3-in-e11

Novel Mmpl3 inhibitor, indirectly blocking translocation of Trehalose Monomycolates across the IM

923204-35-7
DCC3426 Mms-350

Highly water-soluble antifibrotic agent, reducing the profibrotic phenotype induced in vitro in primary human fibroblasts and ameliorating bleomycin-induced pulmonary fibrosis in vivo

DCC3427 Mmv001239

Novel inhibitor of lanosterol-14-alpha-demethylase (TcCyp51)

DCC3428 Mmv006764

The first small-molecule anti-plasmodial agent, disrupting rosetting, simultaneously restoring microcirculation and reduce parasite load

DCC3429 Mmv007564

Novel antimalarial agent against asexual stages of P. falciparum

950291-33-5
DCC3430 Mmv007839

Novel potent Plasmodium lactate transporter PfFNT

381710-03-8
DCC3431 Mmv008138

Novel MEP pathway-targeting antimalarial agent

1217513-24-0
DCC3432 Mmv009108

Novel antimalarial agent with increased efficacy against one or more pfatp4 mutated clones

DCC3433 Mmv019662

Novel Inhibitor of Plasmodium falciparum

DCC3434 Mmv022029

Novel antischistosomal agent against chronic S. mansoni infection

DCC3435 Mmv022478

Novel antischistosomal agent against chronic S. mansoni infection

DCC3436 Mmv028038

Novel antimalarial agent with increased efficacy against one or more pfatp4 mutated clones

DCC3437 Mmv085203

Novel inhibitor of Plasmodium falciparum, killing both blood- and sexual-stage P. falciparum parasites

385419-89-6
DCC3438 Mmv396719

Novel antimalarial agent against Plasmodium falciparum

848218-16-6
DCC3439 Mmv665916

Novel antimalarial agent, targeting P. falciparum farnesyltransferase PfFT, showing remarkable growth inhibition with EC50 value of 0.4 µM and presenting good selectivity index (SI > 250)

896356-25-5
DCC3440 Mmv666693

Selective allosteric inhibitor of Plasmodium Kinesin-5

312527-99-4
DCC3441 Mmv675939

Novel potent inhibitor of P. falciparum asexual blood stages, inhibiting heme detoxification

DCC3442 Mmv676477

Novel potent broad antiparasitic agent against intracellular Leishmania amastigotes, Trypanosoma brucei, and Plasmodium falciparum

1003799-04-9
DCC3443 Mmv693183

First-in-class acetyl-CoA synthetase (AcAS) inhibitor, showong single digit nanomolar in vitro activity against P. falciparum and P. vivax clinical isolates, and potently blocking P. falciparum transmission to Anopheles mosquitoes

DCC3444 Mnd Oxalate

Novel anticancer agent, inducing apoptosis, inhibiting migration and invasion

DCC3445 Mnk1/2-in-9

Novel highly potent and selective MNK1/2 kinases inhibitor

DCC3446 Mnk2-in-8e

Potent and selective Mnk2 inhibitor

DCC3447 Mntmpyp Pentachloride

Cell-permeable superoxide dismutase (SOD) mimetic

100012-18-8
DCC3448 Molibresib Besylate

Novel inhibitor of the BET (Bromodomain and Extra-Terminal) family of bromodomain-containing proteins with potential antineoplastic activity

1895049-20-3
DCC3449 Momelotinib Dihydrochloride Featured

Momelotinib (dihydrochloride) is a JAK1/JAK2 inhibitor that also antagonizes ACVR1, leading to downregulation of Hepcidin expression and increased availability of iron for erythropoiesis. Momelotinib (dihydrochloride) can reduce transfusion burden and spleen enlargement caused by myelofibrosis, showing potential value in research and application within the field of myelofibrosis.

1380317-28-1
DCC3450 Momordicoside L

Natural antioxidant and antidiabetic agent

81348-83-6
DCC3451 Mon-dnj

Novel iminosugar, downregulatiing the interferon γ receptor by dengue virus

615253-61-7
DCC3452 Moracin T

Natural potent antioxidant agent

1146113-27-0
DCC3453 Morellic Acid

Natural analogue of (-)-gambogic acid acting as a potent inhibitor of global predominant MRSA USA300

5304-71-2
DCC3454 Mosapramine Dihydrochloride

Potent dopamine antagonist with high affinity to the D2, D3, and D4 receptors, and with moderate affinity for the 5-HT2 receptors

98043-60-8
DCC3455 Naucledine

Natural antibacterial, antileishmanial, and antifungal agent

26238-84-6
DCC3456 Mp-10 Succinate

Potent and Specific PDE10A inhibitor

1037309-45-7
DCC3457 Mp1104

Novel mixed kappa-delta opioid receptor agonist with anti-cocaine properties and reduced side-effects in rats

DCC3458 Mpges-1 Inhibitor-2

Novel potent and selective microsomal prostaglandin E synthase-1 (mPGES-1) inhibitor

DCC3459 mpi621

Novel anti-cancer agent, being more potent and safer than conventional indomethacin

1428774-23-5
DCC3460 Mpk576

Novel selective class IIb histone deacetylase inhibitor (HDACi), dose-dependently decreasing the viability of Acanthamoeba trophozoites

DCC3461 Mpo-0029

Potent and selective COX-2 inhibitor

248281-84-8
DCC3462 Mpp Dihydrochloride

Specific estrogen receptor α (ERα) antagonist

911295-24-4
DCC3463 Mpro-in-n3

Novel main protease (Mpro) inhibitor, inhibiting MHV-A29, HCoV-229E, FOPV replication, and SARS-CoV-2 viral cell entry

884650-98-0
DCC3464 mps1 Inhibitor I

Novel Mps1 Kinase Inhibitor

1226900-59-9
DCC3465 Mps-bay2b

Novel inhibitor of MPS1

1263420-68-3
DCC3466 Mpt0b206

Novel tubulin polymerization inhibitor

DCC3467 Mpt0b451

Novel Dual HDAC6 and Tubulin Inhibitor, Displaying Anti-tumor Ability in Human Cancer Cells

DCC3468 Mptp-in-22

Novel mitochondrial permeability transition pore (mPTP) inhibitor

1223569-03-6
DCC3469 Mpx-007

Novel potent and selective antagonist of GluN2A-containing NMDA receptors

1688685-29-1
DCC3470 Mq02-439

Novel highly potent and selective 5-HT2C agonist

DCC3471 Mr22388

Novel, potent inducer of apoptosis via the MAP kinase pathways. Inhibitor of several kinases including the tyrosine kinase FLT3-ITD

258270-07-4
DCC3472 Mr6-31-2

Novel inhibitor of the main protease (Mpro) of SARS-CoV-2

DCC3473 Mrgprx1 Pam 1t

Novel positive allosteric modulator (PAM) of mas-related G protein-coupled receptor X1 (MRGPRX1), reducing behavioral heat hypersensitivity in humanized MRGPRX1 mice, demonstrating the therapeutic potential in treating neuropathic pain

DCC3474 Mrgx1-activator-1

Activator of MrgX1 receptor signaling

793731-95-0
DCC3475 Mri-1891

Novel peripheral CB1R antagonist, being highly biased toward inhibiting CB1R-induced β-arrestin-2 (βArr2) recruitment over G-protein activation

DCC3476 Mrl-248

Novel potent and selective RORγT inhibitor, showing no appreciable activity against a panel of related nuclear hormone receptors

DCC3477 Mrl-299

Novel potent RORγT inhibitor

DCC3478 Mrl-367

Novel potent and selective RORγT inhibitor, showing no appreciable activity against a panel of related nuclear hormone receptors

DCC3479 Mrl-770

Novel selective and reproducible inhibitor of DNA synthesis in E. coli JL553

DCC3480 Mrs2220

Selective enhancer of the ATP effects at fast desensitizing P2X (P2X1 and P2X3) receptors

1027168-08-6
DCC3481 mrs2690

Potent P2Y14 receptor agonist

15039-58-4
DCC3482 mrs2693 Trisodium

Selective P2Y6 agonist

911391-37-2
DCC3483 mrs2768

Selective P2Y2 agonist

1047980-83-5
DCC3484 mrs2957

Potent P2Y6 agonist

1228271-30-4
DCC3485 Mrs2964

Potent and selective P2Y6 receptor agonist

DCC3486 Mrs4598

Novel highly potent human CD73 inhibitor (K i = 0.673 nM)

DCC3487 Mrs4608

Novel potent antagonist of P2Y 14 receptor (P2Y 14 R) (IC 50 ~20 nM at hP2Y 14 R/mP2Y 14 R)

DCC3488 Mrs4654

Novel potent P2Y14 Receptor Antagonist (IC 50 , 15 nM)

DCC3489 Mrs7396

Bitopic fluorescent antagonist of the A2A adenosine receptor

DCC3490 Mrs7469

Novel highly selective A1 adenosine receptor (A1AR) agonist

DCC3491 Mrs7591

Novel Partial Agonist of Human and Mouse A3 Adenosine Receptors (Ki = 10.9/17.8 nM, at human/mouse A3AR)

DCC3492 Mrs7799

Novel highly potent A3 adenosine receptor (A3AR) antagonist with Kd values (nM): 0.55 (human), 3.74 (mouse), and 2.80 (rat)

DCC3493 Mrt-68601 Hydrochloride

Potent inhibitor of TANK-binding kinase-1 (TBK1)/IKKepislon kinases

1962928-25-1
DCC3494 Mrt-92 Hydrochloride

Novel inhibitor of Hedgehog signaling by blocking overlapping binding sites in the transmembrane domain of the Smoothened receptor

1428307-52-1
DCC3495 Mrz-8676

Novel, selective, orally bioavailable, negative allosteric modulator of subtype 5 metabotropic glutamate receptors (mGluR5)

872122-36-6
DCC3496 ms0017509

Inhibitor of DNA damage repair

21945-37-9
DCC3497 ms0019266

Novel inhibitor of DNA damage repair

124285-22-9
DCC3498 Ms2126

Novel inhibitor of Human p53 and CREB Binding Protein (CREBBP) interaction

16078-42-5
DCC3499 Ms2177

Novel potent and selective SETD8 inhibitor

DCC3500 Ms2i6a

Mitochondrial tRNA-specific modification, regulating efficient mitochondrial translation and energy metabolism in mammals

20859-00-1
DCC3501 Msc2524070

Novel potent tankyrase (TNKS) inhibitor (EC 50 : 2 nM)

DCC3502 Msc-4381

Novel inhibitor of SLC16A3

DCC3503 Msd-496486311

Novel potent and selective PI3Kδ inhibitor

DCC3504 Msk-195

Potent TRPV1 agonist

289902-82-5
DCC3505 Mßl-in-2i

Novel potent broad-spectrum metallo-β-lactamase (MβL) inhibitor, inhibiting the MβLs NDM-1, VIM-2, ImiS, and L1

305376-89-0
DCC3506 Mt1/2 Agonist (s)-3b

Novel BBB permeable potent MT1 and MT2 ligand (MT1, Ki = 0.031 nM; MT2, Ki = 0.070 nM) with good metabolic stability in human hepatic microsomes

DCC3507 Mtc420

Novel antituberculosis agent. targeting the respiratory chain of Mycobacterium tuberculosis (Mtb) and being effective against multi drug resistant (MDR) Mtb

2088930-66-7
DCC3508 Mtd12813

Novel minimized theta-defensin, being highly effective against CRE pathogens K. pneumoniae and E. coli in vivo, significantly enhancing survival by promoting rapid host-mediated bacterial clearance and by modulating pathologic cytokine responses, restorin

DCC3509 Mtdl-4e

Novel resveratrol-based multitarget-directed ligand, cellularly activating the NRF2-ARE pathway (CD = 9.83 μM), selectively inhibiting both hMAO-B and QR2 (IC 50 s = 8.05 and 0.57 μM), and promoting hippocampal neurogenesis

DCC3510 Mthp Hydrobromide

Selective antagonist of melanocortin-4 receptor (MC4R)

325959-81-7
DCC3511 Mtmox32e

Novel Mithramycin A (MTM) 2'-oxime (MTMox) conjugate, displaying an 11-fold increase in plasma exposure and improved efficacy in an Ewing sarcoma xenograft

DCC3512 Mtor Inhibitor-7

Novel, potent, and selective brain-penetrant ATP-competitive mTOR inhibitor

DCC3513 Mtor/hdac1-in-12l

Novel potent dual inhibitor of mTOR and HDAC1

DCC3514 Mtorc1-in-1

Novel selective inhibitor of mTORC1, yielding potent inhibition of glucose uptake

DCC3515 Mtorc1-in-i

Novel selective mTORC1 inhibitor, directly targeting class I glucose transporters

DCC3516 Mtor-in-17

Novel mTOR inhibitor, exhibiting potent anticancer activities against four tumor cell lines, including MCF-7, HeLa, MGC-803, and C6, inducing cell death via apoptosis by targeting both mTORC1 and mTORC2 within cells and arrests the cell cycle of HeLa at t

DCC3517 Mtpdds

Novel mitochondria-targeted photoactivatable real-time probe, being phototriggered by either UV (one-photon) or NIR (two-photon) light to form a fluorescent coumarin product and facilitate the release of drug payload

DCC3518 Mtsea Hydrobromide

Useful probe in the mapping of membrane proteins, such as ion channels and transports proteins, as well as enzymes and receptors.

16599-33-0
DCC3519 Mtsea Hydrochloride

Useful probe in the mapping of membrane proteins, such as ion channels and transports proteins, as well as enzymes and receptors.

37597-96-9
DCC3520 Multitarget Ligand B6

Novel potent multitarget ligand

220459-72-3
DCC3521 Mura-in-1 (zinc6129841)

Novel potent MurA inhibitor

577789-80-1
DCC3522 Murizatoclax

Novel potent and selective MCL-1 inhibitor

2245848-05-7
DCC3523 Mutant Idh1 Inhibitor

Novel potent mutant IDH1 R132H inhibitor

1429180-08-4
DCC3524 Mv061194

Novel potent and selective cathepsin K (Cat K) inhibitor

1021423-50-6
DCC3525 Mw01-2-151srm

CNS-penetrant, selective restorer of injury- or disease-induced overproduction of proinflammatory cytokines towards homeostasis. Selective suppressor of beta amyloid (Aβ)-induced glia proinflammatory cytokine production

886208-65-7
DCC3526 mw1219

Novel GPR119 agonist with Anti-Diabetic Efficacy in db/db Mice

54087-06-8
DCC3527 Mwp00839

Novel mitophagy activator

DCC3528 mycothiol

Major thiol in most actinomycetes involved in mycothiol biosynthesis and mycothiol-dependent enzymes such as mycothiol-dependent formaldehyde dehydrogenase and mycothione reductase

192126-76-4
DCC3529 Mycro1

Novel inhibitor of the protein-protein interactions between the bHLHZip proteins c-Myc and Max

313987-85-8
DCC3530 Mycro2

Novel inhibitor of the protein-protein interactions between the bHLHZip proteins c-Myc and Max

314049-21-3
DCC3531 My-d-4

Novel inhibitor of zinc finger DHHC domain-containing (zDHHC) enzymes

DCC3532 Myotoxin Ii (105-117)

Myotoxin II fragment

223596-96-1
DCC3533 myovin-1

Novel potent, reversible and uncompetitive inhibitor of actin-stimulated ATPase activity of myosin V

1259177-59-7
DCC3534 Myra-a

Novel inducer of apoptosis in a Myc-dependent manner, inhibiting Myc-driven transformation and disrupting MYC-Max interaction

3900-43-4
DCC3535 Myrtucommulone

Inhibitor of the chaperonin activity of HSP60, correlating to LONP and LRP130 aggregation

54247-21-1
DCC3536 Myxopyronin A

Bacterial RNA polymerase (RNAP) inhibitor

88192-98-7
DCC3537 Mzp-54

Novel potent and selective PROTAC degrader of BRD3/4

2010159-47-2
DCC3538 N,n-dimethylsphingosine

Competitive inhibitor of both SPHK1 and SPHK2

119567-63-4
DCC3539 n00236460

Glucokinase activator (GKA)

1466419-40-8
DCC3540 N6-allyladenosine

Novel RNA labeling probe through both metabolic and enzyme-assisted manners

15763-12-9
DCC3541 N6-methyl-d3-adenosine

Deuterium labeled m6A used in important m6A physiological pathways related studies

139896-43-8
DCC3542 Na-aaf

Alkylating agent, forming DNA adducts at the C-8 position in guanine, resulting in single strand breaks, demonstrating carcinogenic action

6098-44-8
DCC3543 Nabiximols

Delta-9-tetrahydrocannabinol (THC)/cannabidiol (CBD) combination for the treatment of multiple sclerosis (MS)-related moderate to severe spasticity

56575-23-6
DCC3544 N-acetylloline

Derivative of loline

4914-36-7
DCC3545 N-adamantanylglycinamide Hbr

Novel antiviral agent against the replication of influenza virus A/H3N2 subtype in Madin-Darby canine kidney (MDCK) cells

54993-13-4
DCC3546 Nadide

Coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate linkage

53-84-9
DCC3547 Nadph Tetrasodium Salt

Electron donor and cofactor for many redox enzymes including nitric oxide synthetase

2646-71-1
DCC3548 Nafoxidine

Partial estrogen antagonist, inhibiting angiogenesis in some tissues by blocking the effects of fibroblast growth factor (FGF) and vascular endothelial growth factor (VEGF), inducing oxidative stress, protein kinase C and calcium signaling

1845-11-0
DCC3549 Nag-26

Novel potent full agonist for orexin receptor

DCC3550 Nai003

Novel highly selective antibacterial agent against Propionibacterium acnes

1888304-21-9
DCC3551 Nalbuphine Hydrochloride

Mixed agonist/antagonist opioid modulator, binding with high affinity to the MOR and KOR, and having relatively low affinity for the DOR

23277-43-2
DCC3552 Naph-o2

Novel fluorescent probe for detection of endogenously produced Naph-O2˙– in living cells and tissues

DCC3553 Naphthyridine-azaquinolone

Novel repeat-structure-specific DNA ligand, specifically binding slipped-CAG DNA intermediates of expansion mutations

DCC3554 Naphyrone Hydrochloride

Triple reuptake inhibitor

850352-11-3
DCC3555 Napi2b Inhibitor 15

Novel Gut-Restricted Inhibitor of Intestinal Sodium-Dependent Phosphate Transport Protein 2b (NaPi2b) for the Treatment of Hyperphosphatemia

DCC3556 Napitane Mesylate

Antagonist of alpha-2 adrenergic receptors and inhibitor of the neuronal uptake of norepinephrine

149189-73-1
DCC3557 Napsagatran

Inhibitor of extrinsic and intrinsic thrombin generation, inhibiting clot-bound and free (fluid-phase thrombin)

159668-20-9
DCC3558 N-arachidonoyl Taurine

Activator of the transient receptor potential vanilloid (TRPV) channels TRPV1 and TRPV4

119959-65-8
DCC3559 Nargenicin

Natural DnaE1 blocker, inducing a DNA damage response in Mycobacterium tuberculosis (Mtb) and inhibiting growth by blocking the replicative DNA polymerase, DnaE1

70695-02-2
DCC3560 Tylophorine

Potent suppressor of inducible nitric oxide synthase (iNOS; NOS II)

482-20-2
DCC3561 Nav1.1-in-b

Novel selective NaV1.1 inhibitor, reducing visceral hypersensitivity

924862-21-5
DCC3562 Nav1.7 Blocker-13

Novel selective blocker of NaV1.7 with little affinity for NaV 1.2, 1.3, or 1.6, being more potent at human vs guinea pig NaV1.7

DCC3563 Nav1.7 Blocker-24

Potent and selective blocker of voltage-gated Nav1.7 sodium channels

1315451-25-2
DCC3564 Nav1.7 Blocker-801

Potent NaV1.7 blocker, being 5-10 fold more potent than NaV 1.2 and NaV 1.6

1235403-75-4
DCC3565 Navarixin

Novel CXC chemokine receptor 2 (CXCR2) antagonist

862464-58-2
DCC3566 Naveglitazar

Dual peroxisome proliferator-activated receptor gamma and alpha (PPARgamma and PPARalpha) agonist

476436-68-7
DCC3567 Naxifylline

Potent and selective A1 adenosine receptor antagonist

166374-49-8
DCC3568 Nb-360

Biological Active Reagents

1262857-73-7
DCC3569 Nb-caged Tyrosine Hydrochloride

L-Tyrosine caged with photosensitive ortho-nitrobenzyl side chain

207727-86-4
DCC3570 Nbd-09027

Novel HIV-1 entry inhibitor

1376434-43-3
DCC3571 Nbd-10007

Novel HIV-1 entry inhibitor

1375736-65-4
DCC3572 Nbd-14136

Novel CD4-mimetic HIV-1 entry inhibitor

DCC3573 N-bn-thaz Fumarate

Potent agonist of the human 5-HT2A and 5-HT2C receptors

125115-67-5
DCC3574 Nboh-2c-cn Hydrochloride

Potent and selective 5-HT2A receptor agonist

1539266-32-4
DCC3575 Nbti-5463

Novel bacterial type II topoisomerase inhibitor with activity against gram-negative bacteria and in vivo efficacy

DCC3576 nc00094221

M. tuberculosis Dihydrofolate Reductase Inhibitor

139337-61-4
DCC3577 Nc2213

Novel inhibitor of methionine aminopeptidase 2 (MetAP2)

DCC3578 Ncats-sm1440

First-in-class, potent, and selective Lactate dehydrogenase inhibitor

DCC3579 Ncats-sm1441

First-in-class, potent, and selective Lactate dehydrogenase inhibitor

DCC3580 Ncb0970

Less active trans-isomer of NCB-0846, acting as the negative control for NCB-0846, showing 13-fold weaker TNIK enzyme-inhibitory activity

DCC3581 Ncdm-32

Potent pan KDM Inhibitor, inhibiting KDM2A, KDM7A, KDM7B, KDM4A, KDM4C, and KDM5A

DCC3582 Ncgc00117362

Novel inhibitor of ovarian cancer metastasis, adhesion, invasion and proliferation

DCC3583 Ncgc00120943

Novel Agonist for Human Resolvin D1 Receptor DRV1 with Pro-Resolving Functions

902842-20-0
DCC3584 ncgc00161856

The first small-molecule inverse agonist for the thyroid-stimulating hormone receptor (TSHR)

361187-13-5
DCC3585 ncgc00242595

TSHR neutral antagonist, inhibiting stimulated signaling but not basal signaling

1338824-23-9
DCC3586 Ncgc00249987

Novel allosteric Eya2 phosphatase inhibitor, specifically targeting migration, invadopodia formation, and invasion of lung cancer cells

DCC3587 Ncgc00262654

Novel AMA1-RON2 Inhibitor

DCC3588 Ncgc2327

Novel potent inhibitor of IRAK1/4 and FLT3

DCC3589 Nco-04

Novel SIRT1 inhibitor, inducing cell death in adult T-cell leukaemia cells

DCC3590 Ncrw0005-f05

Novel GPR139 receptor agonist

342779-66-2
DCC3591 Ncs-382

Analogue of γ-hydroxybutyric acid (GHB), acting as a substrate for both the monocarboxylate transporter subtype 1 (MCT1) and subtype 4 (MCT4)

131733-92-1
DCC3592 Ncs-8591

Beclin 1 mimetic, selectively binding to Bcl-xL and inducing autophagy, showing potent cytotoxicity in PC-3, PC-3a and DU145 prostate cancer cells

6286-97-1
<Prev1...169170171172173...191Next>